IP Library Granted Patent US 9,643,916
Granted Patent B2
US 9,643,916 · App. 15/077,447 · Granted May 9, 2017

Low molecular weight cationic lipids for oligonucleotide delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,643,916
App. No.
15/077,447
Granted
May 9, 2017
Kind
B2
Abstract

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

Claims (20)

1. A cationic lipid of Formula A:

wherein:

R 1 and R 2 are independently selected from H, (C 1 -C 6 )alkyl, heterocyclyl, and polyamine, wherein said alkyl, heterocyclyl and polyamine are optionally substituted with one to three substituents selected from R′, or R 1 and R 2 can be taken together with the nitrogen to which they are attached to form a monocyclic heterocycle with 4-7 members optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic heterocycle is optionally substituted with one to three substituents selected from R′;

R′ is independently selected from halogen, R″, OR″, SR″, CN, CO 2 R″ or CON(R″) 2 ;

R″ is independently selected from H and (C 1 -C 6 )alkyl, wherein said alkyl is optionally substituted with halogen and OH;

L 1 is selected from

 and

L 2 is selected from C 3 -C 13 alkyl and C 3 -C 13 alkenyl, said alkyl and alkenyl are optionally substituted with one or more substituents selected from R′;

or any pharmaceutically acceptable salt or stereoisomer thereof.

2. A cationic lipid according to claim 1 ,

wherein:

R 1 and R 2 are each methyl;

L 1 is selected from

 and

L 2 is selected from C 3 -C 13 alkyl and C 3 -C 13 alkenyl;

or any pharmaceutically acceptable salt or stereoisomer thereof.

3. A lipid nanoparticle comprising a cationic lipid of claim 1 .

4. The lipid nanoparticle of claim 3 , wherein the lipid nanoparticle comprises oligonucleotides.

5. The lipid nanoparticle of claim 4 , wherein the oligonucleotide are siRNA or miRNA.

6. The lipid nanoparticle of claim 4 wherein the oligonucleotide are siRNA.

Assignments (3)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2016
From: BUDZIK, BRIAN W.; COLLETTI, STEVEN L.; DAVIS, JENNIFER R.; HILLS, IVORY D.; SEIFRIED, DARLA DANILE; STANTON, MATTHEW G.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 039820/0297 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2016
From: MERCK SHARP & DOHME CORP.
To: SIRNA THERAPEUTICS, INC.
Reel/Frame 039820/0328 →